Biogened Past Earnings Performance

Past criteria checks 4/6

Biogened has been growing earnings at an average annual rate of 31%, while the Pharmaceuticals industry saw earnings growing at 12.9% annually. Revenues have been growing at an average rate of 19.3% per year. Biogened's return on equity is 12.4%, and it has net margins of 4.5%.

Key information

31.0%

Earnings growth rate

33.2%

EPS growth rate

Pharmaceuticals Industry Growth29.4%
Revenue growth rate19.3%
Return on equity12.4%
Net Margin4.5%
Last Earnings Update30 Sep 2024

Recent past performance updates

Impressive Earnings May Not Tell The Whole Story For Biogened (WSE:BGD)

Aug 22
Impressive Earnings May Not Tell The Whole Story For Biogened (WSE:BGD)

Biogened's (WSE:BGD) Promising Earnings May Rest On Soft Foundations

Feb 21
Biogened's (WSE:BGD) Promising Earnings May Rest On Soft Foundations

Recent updates

Biogened (WSE:BGD) Takes On Some Risk With Its Use Of Debt

Nov 06
Biogened (WSE:BGD) Takes On Some Risk With Its Use Of Debt

A Piece Of The Puzzle Missing From Biogened S.A.'s (WSE:BGD) 25% Share Price Climb

Aug 28
A Piece Of The Puzzle Missing From Biogened S.A.'s (WSE:BGD) 25% Share Price Climb

Impressive Earnings May Not Tell The Whole Story For Biogened (WSE:BGD)

Aug 22
Impressive Earnings May Not Tell The Whole Story For Biogened (WSE:BGD)

Investors Give Biogened S.A. (WSE:BGD) Shares A 37% Hiding

May 23
Investors Give Biogened S.A. (WSE:BGD) Shares A 37% Hiding

Here's Why Biogened (WSE:BGD) Has A Meaningful Debt Burden

May 09
Here's Why Biogened (WSE:BGD) Has A Meaningful Debt Burden

Biogened's (WSE:BGD) Promising Earnings May Rest On Soft Foundations

Feb 21
Biogened's (WSE:BGD) Promising Earnings May Rest On Soft Foundations

Is Biogened (WSE:BGD) A Risky Investment?

Feb 01
Is Biogened (WSE:BGD) A Risky Investment?

Biogened S.A. (WSE:BGD) Looks Just Right With A 37% Price Jump

Feb 01
Biogened S.A. (WSE:BGD) Looks Just Right With A 37% Price Jump

We Think Biogened (WSE:BGD) Can Stay On Top Of Its Debt

Jun 30
We Think Biogened (WSE:BGD) Can Stay On Top Of Its Debt

Biogened (WSE:BGD) Seems To Use Debt Quite Sensibly

Oct 08
Biogened (WSE:BGD) Seems To Use Debt Quite Sensibly

Is Biogened (WSE:BGD) A Risky Investment?

Jun 29
Is Biogened (WSE:BGD) A Risky Investment?

Does Biogened (WSE:BGD) Have A Healthy Balance Sheet?

Mar 25
Does Biogened (WSE:BGD) Have A Healthy Balance Sheet?

These 4 Measures Indicate That Biogened (WSE:BGD) Is Using Debt Reasonably Well

Dec 09
These 4 Measures Indicate That Biogened (WSE:BGD) Is Using Debt Reasonably Well

Biogened (WSE:BGD) Has A Somewhat Strained Balance Sheet

Jul 29
Biogened (WSE:BGD) Has A Somewhat Strained Balance Sheet

Biogened (WSE:BGD) Seems To Use Debt Quite Sensibly

Apr 30
Biogened (WSE:BGD) Seems To Use Debt Quite Sensibly

Is Biogened (WSE:BGD) A Risky Investment?

Jan 24
Is Biogened (WSE:BGD) A Risky Investment?

Revenue & Expenses Breakdown

How Biogened makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

WSE:BGD Revenue, expenses and earnings (PLN Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 241075640
30 Jun 241065610
31 Mar 241004580
31 Dec 23965550
30 Sep 23924470
30 Jun 23904460
31 Mar 23854450
31 Dec 22803420
30 Sep 22774410
30 Jun 22724360
31 Mar 22703360
31 Dec 21652350
30 Sep 21572330
30 Jun 21542330
31 Mar 21501300
31 Dec 20481300
30 Sep 20492290
30 Jun 20481290
31 Mar 20481290
31 Dec 19471280
30 Sep 19451280
30 Jun 19441270
31 Mar 19411260
31 Dec 18401260
30 Sep 18391240
30 Jun 18391240
31 Mar 18361220
31 Dec 17341210
30 Sep 17301190
30 Jun 17311200
31 Mar 17291190
31 Dec 16291190
30 Sep 16322210
30 Jun 16312200
31 Mar 16313190
31 Dec 15303180
30 Sep 15302180
30 Jun 15261150
31 Mar 15241140
31 Dec 14231130
30 Sep 14201120
30 Jun 14211120
31 Mar 14221130
31 Dec 13222120

Quality Earnings: BGD has high quality earnings.

Growing Profit Margin: BGD's current net profit margins (4.5%) are higher than last year (4.1%).


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: BGD's earnings have grown significantly by 31% per year over the past 5 years.

Accelerating Growth: BGD's earnings growth over the past year (28.6%) is below its 5-year average (31% per year).

Earnings vs Industry: BGD earnings growth over the past year (28.6%) exceeded the Pharmaceuticals industry 10.2%.


Return on Equity

High ROE: BGD's Return on Equity (12.4%) is considered low.


Return on Assets


Return on Capital Employed


Discover strong past performing companies